GlassScriptPhysician profile
Bruce H Wallach
NPI 1649256066
$10,587.68
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $321 · 2021: $3,905 · 2022: $3,274 · 2023: $2,337 · 2024: $95.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,000 · Education: $262 · Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,000.00 |
| Education | $261.99 |
| Food and Beverage | $170.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $8,750.00 | 2021-2023 | |
| Daiichi Sankyo INC. | $241.79 | 2022 | |
| Amgen INC. | $221.77 | 2019-2020 | |
| Seagen INC. | $215.43 | 2019-2023 | |
| Puma Biotechnology, INC. | $114.24 | 2019 | |
| Gilead Sciences, INC. | $104.61 | 2019-2024 | Trodelvy |
| Janssen Biotech, INC. | $99.00 | 2021 | |
| Incyte Corporation | $95.97 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $74.69 | 2019-2022 | |
| Genzyme Corporation | $70.94 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $59.00 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $58.52 | 2023 | Rolvedon |
| Astrazeneca Pharmaceuticals LP | $55.58 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.16 | 2019 | |
| Eisai INC. | $32.14 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $31.46 | 2019 | |
| Verastem, INC. | $31.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.10 | 2019-2020 | |
| Mirati Therapeutics, INC. | $18.81 | 2023 | Krazati |
| Ipsen Biopharmaceuticals, INC | $17.73 | 2020 | |
| Exelixis INC. | $17.37 | 2023 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $17.17 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.53 | 2024 | Vivimusta |
| Sumitomo Pharma America, INC. | $16.12 | 2023 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $14.96 | 2019 | |
| Pfizer INC. | $14.80 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2019 | |
| Astellas Pharma US INC | $14.68 | 2019 | |
| Merck Sharp & Dohme LLC | $14.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2019 | |
| Clovis Oncology, INC. | $13.62 | 2019 | |
| Glaxosmithkline, LLC. | $13.20 | 2021 | |
| Sirtex Medical INC | $12.76 | 2019 | |
| Karyopharm Therapeutics INC. | $12.57 | 2020 | |
| Lilly USA, LLC | $12.26 | 2019 | |
| Genentech USA, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Wallach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.